ACRS -4.13 to 0.62, might be a speculative buy at this price since the company is a 4 trick pony, not just the 1 trick that failed. The 52wk high is $18, so tax loss selling probably a factor till year end, but the sellers may flush out quickly ..... how much lower can it go with all that cash and other pipeline prospects, however dubious they may be ?
PR -
Based on the overall program results, Aclaris will discontinue further development of the ATI-450 program, including halting enrollment of Aclaris’ ongoing Phase 2a trial of zunsemetinib in psoriatic arthritis.
“We are deeply disappointed with the results of this trial and for patients suffering from rheumatoid arthritis. We would like to thank the patients and investigators for their participation in the trial, and I am proud of our team for their commitment to its execution,” stated Doug Manion, M.D., Aclaris’ Chief Executive Officer. “Despite this setback, we continue to look forward to the upcoming results of our Phase 2b trial of ATI-1777 in atopic dermatitis and initiating our Phase 2 clinical development program for ATI-2138.”
